Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2009, Pages 279-294

  Smaldone, Costantino ^a   Brugaletta, Salvatore ^a   Pazzano, Vincenzo ^a   Liuzzo, Giovanna ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOKINE; DONEPEZIL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; QUINAPRIL; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; IMMUNOLOGIC FACTOR;

ACUTE CORONARY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ATHERECTOMY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DEMENTIA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HASHIMOTO DISEASE; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASE; INFLAMMATION; MEMBRANE; PRENYLATION;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION; MEMBRANES; PRENYLATION;

EID: 74049124552     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789541864     Document Type: Review

References (171)

1. O'Keefe, J.H., Jr.; Cordain, L.; Harris, W.H.; Moe, R.M.; Vogel, R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol., 2004, 43, 2142.
2. Gotto, A.M., Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am. J. Cardiol., 2005, 96, 34F.
3. Amarenco, P.; Labreuche, J.; Lavallee, P.; Touboul, P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke, 2004, 35, 2902.
4. Nassief, A.; Marsh, J.D. Statin therapy for stroke prevention. Stroke, 2008, 39, 1042.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383.
6. Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R.; Macfarlane, P.W.; McKillop, J.H.; Packard, C.J.; for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 1995, 333, 1301.
7. ALLHAT officers and coordinators for the ALLHAT collaborarative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002, 228, 2998.
8. Cannon, C.P.; Braunwald, E.; McCabe, E.B.; Rader, D.J.; Rouleau, J.L.; Belder, R.; Joyal, S.V.; Hill, K.A.; Pfeffer, M.A.; Skene, A.M.; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, 350, 1495.
9. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; McCabe, C.H.; Pfeffer, M.A.; Braunwald, E.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. Creactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352, 20.
10. Ridker, P.M.; Morrow, D.A.; Rose, L.M.; Rifai, N.; Cannon, C.P.; Braunwald, E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J. Am. Coll. Cardiol., 2005, 45, 1644.
11. Mega, J.L.; Morrow, D.A.; Cannon, C.P.; Murphy, S.; Cairns, R.; Ridker, P.M.; Braunwald, E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J. Thromb. Thrombolysis, 2006, 22, 71.
12. Qizilbash, N. Are risk factors for stroke and coronary disease the same? Curr. Opin. Lipidol., 1998, 9, 325.
13. Vaughan, C.J.; Delanty, N.; Basson, C.T. Statin therapy and stroke prevention. Curr. Opin. Cardiol., 2001, 16, 219.
14. Schwartz, G.G.; Olsson, A.G.; Ezekowitz, M.D.; Ganz, P.; Oliver, M.F.; Waters, D.; Zeiher, A.; Chaitman, B.R.; Leslie, S.; Stern, T.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001, 285, 1711.
15. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Brown, B.G.; Ganz, P.; Vogel, R.A.; Crowe, T.; Howard, G.; Cooper, C.J.; Brodie, B.; Grines, C.L.; DeMaria, A.N.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, 291, 1071.
16. Nissen, S.E.; Nicholls, S.J.; Sipahi, I.; Libby, P.; Raichlen, J.S.; Ballantyne, C.M.; Davignon, J.; Erbel, R.; Fruchart, J.C.; Tardif, J.C.; Schoenhagen, P.; Crowe, T.; Cain, V.; Wolski, K.; Goormastic, M.; Tuzcu, E.M. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006, 295, 1556.
17. Derk, T.D.; Jimenz, S.A. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun. Rev., 2006, 5, 25.
18. Vollmer, T.; Key, L.; Durkalski, V.; Tyor, W.; Corboy, J.; Markovic-Plese, S.; Preiningerova, J.; Rizzo, M.; Singh, I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, 2004, 363, 1607.
19. McCarey, D.W.; McInnes, I.B.; Madhok, R.; Hampson, R.; Scherbakov, O.; Ford, I.; Capell, H.A.; Sattar, N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial. Lancet, 2004, 363, 2015.
20. Poynter, J.N.; Gruber, S.B.; Higgins, P.D.; Almog, R.; Bonner, J.D.; Rennert, H.S.; Low, M.; Greenson, J.K.; Rennert, G. Statins and the risk of colorectal cancer. N. Engl. J. Med., 2005, 352, 2184.
21. Libby, P.; Theroux, P. Pathophysiology of coronary artery disease. Circulation, 2005, 111, 3481.
22. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352, 1685.
23. Robertson, A.K.; Hansson, G.K. T cells in atherogenesis: for better or for worse? Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2421.
24. Blazing, M.A.; De Lemos, J.A.; Dyke, C.K.; Califf, R.M.; Bilheimer, D.; Braunwald, E. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecularweight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am. Heart J., 2001, 142, 211
25. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am. J. Cardiol., 1995, 76, 474.
26. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 1996, 335, 1001.
27. Thompson, P.L.; Meredith, I.; Amerena, J.; Campbell, T.J.; Sloman, J.G.; Harris, P.J.; for the Pravastatin in Acute Coronary Treatment (PACT) Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am. Heart J., 2004, 148, e2.
28. De Lemos, J.A.; Blazing, M.A.; Wiviott, S.D.; Lewis, E.F.; Fox, K.A.; White, H.D.; Rouleau, J.L.; Pedersen, T.R.; Gardner, L.H.; Mukherjee, R.; Ramsey, K.E.; Palmisano, J.; Bilheimer, D.W.; Pfeffer, M.A.; Califf, R.M.; Braunwald, E.; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA, 2004, 292, 1307.
29. Pasceri, V.; Patti, G.; Nusca, A.; Pristipino, C.; Richichi, G.; Di Sciascio G.; and on behalf of the ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 2004, 110, 674.
30. Patti, G.; Pasceri, V.; Colonna, G.; Miglionico, M.; Fischetti, D.; Sardella, G.; Montinaro, A.; Di Sciascio, G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol., 2007, 42, 1272.
31. Bell, R.M.; Yellon, D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol., 2003, 41, 508.
32. Smilde, T.J.; Van Wissen, S.; Wollersheim, H.; Trip, M.D.; Kastelein, J.J.P.; Stalenhoef, A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 2001, 357, 577.
33. Kastelein, J.J.P.; Akdim, F.; Stroes, E.S.G.; Zwinderman, A.H.; Bots, M.L.; Stalenhoef, A.F.H.; Visseren, F.L.G.; Sijbrands, E.J.G.; Trip, M.D.; Stein, E.A.; Gaudet, D.; Duivenvoorden, R.; Veltri, E.P.; Marais, A.D.; De Groot, E. Ezetimibe and Simvastatin in Hypercolesterolemia Enhances Atherosclerosis Regression (ENHANCE) investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med., 2008, 358, 1431.
34. Piorkowsky, M.; Fischer, S.; Stellbaum, C.; Jaster, M.; Martus, P.; Morguet, A.J.; Schultheiss, H.P.; Rauch, U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J. Am. Coll. Cardiol., 2007, 49, 1035.
35. Underhill, H.R.; Yuan, C.; Zhao, X.; Kraiss, L.W.; Parker, D.L.; Saam, T.; Chu, B.; Takaya, N.; Liu, F.; Polissar, N.L.; Neradilek, B.; Raichlen, J.S.; Cain, V.A.; Waterton, J.C.; Hamar, W.; Hatsukami, T.S. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J., 2008, 155, 584.e1.
36. Solem, J.; Levin, M.; Karlsson, T.; Grip, L.; Albertsson, P.; Wiklund, O. Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment. J. Intern. Med., 2006, 259, 267
37. Shimada, K.; Miyauchi, K.; Daida, H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation, 2004, 109, e213.
38. Liuzzo, G.; Kopecky, S.L.; Frye, R.L.; O'Fallon, W.M.; Maseri, A.; Goronzy, J.J.; Weyand, C.M. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation, 1999, 100, 2135.
39. Liuzzo, G.; Goronzy, J.J.; Yang, H.; Kopecky, S.L.; Holmes, D.R.; Frye, R.L.; Weyand, C.M. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation, 2000, 101, 2883.
40. Liuzzo, G.; Biasucci, L.M.; Trotta, G.; Brugaletta, S.; Pinnelli, M.; Digianuario, G.; Rizzello, V.; Rebuzzi, A.G.; Rumi, C.; Maseri, A.; Crea, F. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J. Am. Coll. Cardiol., 2007, 50, 1450.
41. Brugaletta, S.; Biasucci, L.M.; Pinnelli, M.; Biondi-Zoccai, G.; Di Giannuario, G.; Trotta, G.; Liuzzo, G.; Crea, F. Novel antiinflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart, 2006, 92, 249.
42. Mor, A.; Luboshits, G.; Planer, D.; Keren, G.; George, J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur. Heart J., 2006, 27, 2530.
43. Sardella, G.; De Luca, L.; Francavilla, V.; Accapezzato, D.; Mancone, M.; Sirinian, M.I.; Fedele, F.; Paroli, M. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. Thromb. Res., 2007, 120, 631.
44. Link, A.; Ayadhi, T.; Böhm, M.; Nickenig, G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur. Heart J., 2006, 27, 2945.
45. Tanaka, K.; Soejima, H.; Hirai, N.; Sakamoto, T.; Yoshimura, M.; Kajiwara, I.; Miyao, Y.; Fujimoto, K.; Miyagi, H.; Irie, A.; Nishimura, Y.; Ogawa, H. Comparison of frequency of interferongamma-positive CD4+ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris. Am.. J. Cardiol., 2004, 93, 1547.
46. Cortellaro, M.; Cofrancesco, E.; Arbustini, E.; Rossi, F.; Negri, A.; Tremoli, E.; Gabrielli, L.; Camera, M. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb. Haemost., 2002, 88, 41.
47. Kennedy, J.; Quan, H.; Buchan, A.M.; Ghali, W.A.; Feasby, T.E. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke, 2005, 36, 2072.
48. Nishi, K.; Itabe, H.; Uno, M.; Kitazato, K.T.; Horiguchi, H.; Shinno, K.; Nagahiro, S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1649.
49. Ehara, S.; Ueda, M.; Naruko, T.; Haze, K.; Itoh, A.; Otsuka, M.; Komatsu, R.; Matsuo, T.; Itabe, H.; Takano, T.; Tsukamoto, Y.; Yoshiyama, M.; Takeuchi, K.; Yoshikawa, J.; Becker, A.E. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 2001, 103, 1955.
50. De Caterina, R.; Cipollone, F.; Filardo, F.P.; Zimarino, M.; Bernini, W.; Lazzerini, G.; Bucciarelli, T.; Falco, A.; Marchesani, P.; Muraro, R.; Mezzetti, A.; Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation, 2002, 106, 2543.
51. Alsheikh-Ali, A.A.; Maddukuri, P.V.; Han, H.; Karas, R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J. Am. Coll. Cardiol., 2007, 50, 409.
52. Kuoppala, J.; Lamminpää, A.; Pukkala, E. Statins and cancer: A systematic review and meta-analysis. Eur. J. Cancer, 2008, 44, 2122.
53. Kjekshus, J.; Apetrei, E.; Barrios, V.; Böhm, M.; Cleland, J.G.; Cornel, J.H.; Dunselman, P.; Fonseca, C.; Goudev, A.; Grande, P.; Gullestad, L.; Hjalmarson, A.; Hradec, J.; Jánosi, A.; Kamensk , G.; Komajda, M.; Korewicki, J.; Kuusi, T.; Mach, F.; Mareev, V.; McMurray, J.J.; Ranjith, N.; Schaufelberger, M.; Vanhaecke, J.; van Veldhuisen, D.J.; Waagstein, F.; Wedel, H.; Wikstrand, J.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med., 2007, 357, 2248.
54. Rahmani, M.; Cruz, R.P.; Granville, D.J.; McManus, B.M. Allograft vasculopathy versus atherosclerosis. Circ. Res., 2006, 99, 801.
55. Mahle, W.T.; Vincent, R.N.; Berg, A.M.; Kanter, K.R. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J. Heart Lung Transplant., 2005, 24, 63.
56. Pinney, S.P.; Mancini, D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr. Opin. Cardiol., 2004, 19, 170.
57. Kobashigawa, J.A.; Katznelson, S.; Laks, H.; Johnson, J.A.; Yeatman, L.; Ming Wang, X.; Chia, D.; Terasaki, P.I.; Sabad, A.; Cogert, G.A.; Trosian, K.; Hamilton, M.A.; Moriguchi, J.D.; Kawata, N.; Hage, A.; Drinkwater, D.C.; Stevenson, L.W. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med., 1995, 333, 621.
58. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 34, 425.
59. Maltese, W.A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J., 1990, 65, 241.
60. Zhang, F.L.; Casey, P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem., 1996, 65, 241.
61. Van Aelst, L.; D'Souza-Schorey, C. Rho GTPases and signaling networks. Genes Dev., 1997, 11, 2295.
62. Mackay, D.J.; Hall, A. Rho GTPases. J. Biol. Chem., 1998, 273, 20685.
63. Wang, C.Y.; Liu, P.; Liao, J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14, 37.
64. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature, 1997, 387, 569.
65. Brown, D.A.; London, E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol., 1998, 14, 111.
66. Pralle, A.; Keller, P.; Florin, E.L.; Simons, K.; Horber, J.K. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J. Cell Biol., 2000, 148, 997.
67. rd.; Braciale, T.J. Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells. J. Immunol., 2001, 166, 7009.
68. Xavier, R.; Brennan, T.; Li, Q.; McCormack, C.; Seed, B. Membrane compartmentation is required for efficient T cell activation. Immunity, 1998, 8, 723.
69. Cheng, P.C.; Dykstra, M.L.; Mitchell, M.N.; Pierce, S.K. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J. Exp. Med., 1999, 190, 1549.
70. Lang, G.A.; Maltsev, S.D.; Besra, G.S.; Lang, M.L. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology, 2004, 112, 386.
71. Goebel, J.; Forrest, K.; Flynn, D.; Rao, R.; Roszman, T.L. Lipid rafts, major histocompatibility complex molecules, and immune regulation. Hum. Immunol., 2002, 63, 810.
72. Kuipers, H.F.; Biesta, P.J.; Groothuis, T.A.; Neefjes, J.J.; Mommaas, A.M.; Van den Elsen, P.J. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol- containing microdomains. Hum. Immunol. 2005, 66, 653.
73. Hillyard, D.Z.; Nutt, C.D.; Thomson, J.; McDonald, K.J.; Wan, R.K.; Cameron, A.J.; Mark, P.B.; Jardine, A.G. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis, 2007, 191, 319.
74. Hillyard, D.Z.; Jardine, A.G.; McDonald, K.J.; Cameron, A.J. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis, 2004, 172, 219.
75. Blank, N.; Schiller, M.; Krienke, S.; Busse, F.; Schätz, B.; Ho, A.D.; Kalden, J.R.; Lorenz, H.M. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J. Immunol., 2007, 179, 3613.
76. Hillyard, D.Z.; Cameron, A.J.; McDonalds, K.J.; Thomson, J.; McIntyre, A.; Shiels, P.J. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis, 2004, 175, 305.
77. Ghittoni, R.; Napolitani, G.; Benati, D.; Ulivieri, C.; Patrussi, L.; Laghi Pasini, F.; Lanzavecchia, A.; Baldari, C.T. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur. J. Immunol., 2006, 36, 2885.
78. Holling, T.M.; Schooten, E.; van Den Elsen, P.J. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol., 2004, 65, 282.
79. Kwak, B.; Mulhaupt, F.; Myit, S.; Mach, F. Statins as a newly recognized type of immunomodulator. Nat. Med., 2000, 6, 1399.
80. Kwak, B.; Mulhaupt, F.; Veillard, N.; Pelli, G.; Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly, 2001, 131, 41.
81. Rezaie-Majd, A.; Maca, T.; Bucek, R.A.; Valent, P.; Muller, M.R.; Husslein, P. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Aterioslcer. Thromb. Vasc. Biol., 2002, 22, 1194.
82. Neuhaus, O.; Strasser Fuchs, S.; Fazekas, F.; Kieseier, B.C.; Niederwieser, G.; Hartug, H.P.; Archelos, J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology, 2002, 59, 990.
83. Lawman, S.; Mauri, C.; Jury, E.C.; Cook, H.T.; Eherenstein, M.R. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J. Immunol., 2004, 173, 7641.
84. Yilmaz, A.; Reiss, C.; Tantawi, O.; Weng, A.; Stumpf, C.; Raaz, D.; Ludwig, J.; Berger, T.; Steinkasserer, A.; Daniel, W.G.; Garlichs, C.D. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis, 2004, 172, 85.
85. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78.
86. Townsend, K.P.; Shytle, D.R.; Bai, Y.; San, N.; Zeng, J.; Freeman, M.; Mori, T.; Fernandez, F.; Morgan, D.; Sanberg, P.; Tan, J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res., 2004, 78, 167.
87. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol., 1999, 18, 767.
88. Bobryshev, Y.V.; Lord, R.S. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immuneinflammatory reactions. Cardiovasc. Res., 1998, 37, 799.
89. Warnock, R.A.; Askari, S.; Butcher, E.C.; Von Adrian, U.H. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J. Exp. Med., 1998, 187, 205.
90. Williams, M.B.; Butcher, E.C. Homing of naive and memory T lymphocyte subsets to Peyer's patches, lymph nodes, and spleen. J. Immunol., 1997, 159, 1746.
91. Baggiolini, M. Chemokines and leukocyte traffic. Nature, 1998, 392, 565.
92. Fessler, M.B.; Young, S.K.; Jeyaseelan, S.; Lieber, J.G.; Arndt, P.G.; Nick, J.A.; Worthen, G.S. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Respir. Crit. Care Med., 2005, 171, 606.
93. Fischetti, F.; Carretta, R.; Borotto, G.; Durigutto, P.; Bulla, R.; Meroni, P.L.; Tedesco, F. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin. Exp. Immunol., 2004, 135, 186.
94. Lefer, A.M.; Campbell, B.; Shin, Y.K.; Scalia, R.; Hayward, R.; Lefer, D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation, 1999, 100, 178.
95. Shimizu, K.; Aikawa, M.; Takayama, K.; Libby, P.; Mitchell, R.N. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation, 2003, 108, 2113.
96. McKay, A.; Leung, B.P.; McInnes, I.B.; Thomson, N.C.; Liew, F.Y. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J. Immunol., 2004, 172, 2093.
97. Schramm, R.; Menger, M.D.; Harder, Y.; Schmits, R.; Adam, O.; Weits-Schmidt, G.; Schafers, H.J. Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology, 2006, 120, 3158.
98. Carlos, T.M.; Harlan, J.M. Leukocyte-endothelial adhesion molecules. Blood, 1994, 84, 2068.
99. Dustin, M.L.; Springer, T.A. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature, 1989, 341, 619.
100. Kallen, J.; Welzenbach, K.; Ramage, P.; Geyl, D.; Kriwacki, R.; Legge, G.; Cottens, S.; Weitz-Schmidt, G.; Hommel, U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a Idomain. J. Mol. Biol., 1999, 292, 1.
101. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. G. Nat. Med., 2001, 7, 687.
102. Luttun, A.; Dewerchin, M.; Collen, D.; Carmeliet, P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep., 2000, 2, 407.
103. Libby, P.; Schönbeck, U. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. Circ. Res., 2001, 89, 195.
104. Galis, Z.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 2493.
105. Sukhova, G.K.; Schönbeck, U.; Rabkin, E.; Schoen, F.J.; Poole, A.R.; Billinghurst, R.C.; Libby, P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation, 1999, 99, 2503.
106. Herman, M.P.; Sukhova, G.K.; Libby, P.; Gerdes, N.; Tang, N.; Horton, D.B.; Kilbride, M.; Breitbart, R.E.; Chun, M.; Schönbeck, U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation, 2001, 104, 1899.
107. Porter, K.E.; Naik, J.; Turner, N.A.; Dickinson, T.; Thompson, M.M.; London, N.J. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg., 2002, 36, 150.
108. Koh, K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res., 2000, 47, 648.
109. Ikeda, U.; Shimpo, M.; Ohki, R.; Inaba, H.; Takahashi, M.; Yamamoto, K.; Shimada, K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension, 2000, 36, 325.
110. Hayashidani, S.; Tsutsui, H.; Shiomi, T.; Suematsu, N.; Kinugawa, S.; Ide, T.; Wen, J.; Takeshita, A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002, 105, 868.
111. Bellosta, S.; Via, D.; Canavesi, M.; Pfister, P.; Fumagalli, R.; Paoletti, R.; Bernini, F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1671.
112. Wong, B.; Lumma, W.C.; Smith, A.M.; Sisko, J.T.; Wright, S.D.; Cai, T.Q. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol., 2001, 69, 959.
113. Wilson, S.H.; Herrmann, J.; Lerman, L.O.; Holmes, D.R. Jr; Napoli, C.; Ritman, E.L.; Lerman, A. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation, 2002, 105, 415.
114. Aikawa, M.; Rabkin, E.; Sugiyama, S.; Voglic, S.J.; Fukumoto, Y.; Furukawa, Y.; Shiomi, M.; Schoen, F.J.; Libby, P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001, 103, 276.
115. Crisby, M.; Nordin-Fredriksson, G.; Shah, P.K.; Yano, J.; Zhu, J.; Nilsson, J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 2001, 103, 926.
116. Chase, A.J.; Bond, M.; Crook, M.F.; Newby, A.C. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 765.
117. Cuccurullo, C.; Iezzi, A.; Fazia, M.L.; De Cesare, D.; Di Francesco, A.; Mraro, R.; Bei, R.; Ucchino, S.; Spigonardo, F.; Chiarelli, F.; Schmidt, A.M.; Cuccurullo, F.; Mezzetti, A.; Cipollone, F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2716.
118. Uyemura, K.; Demer, L.L.; Castle, S.C.; Jullien, D.; Berliner, J.A.; Gately, M.K.; Warrier, R.R.; Pham, N.; Fogelman, A.M.; Modlin, R.L. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest., 1996, 97, 2130.
119. Kohno, H.; Sakai, T.; Saito, S.; Okano, K.; Kitahara, K. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Exp. Eye Res., 2007, 84, 569.
120. Gegg, M.E.; Harry, R.; Hankey, D.; Zambarakji, H.; Pryce, G.; Baker, D.; Adamson, P.; Calder, V.; Greenwood, J. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol., 2005, 174, 2327.
121. Chung, H.K.; Lee, I.K.; Kang, H.; Suh, J.M.; Kim, H.; Park, K.C.; Kim, D.W.; Kim, Y.K.; Ro, H.K.; Shong, M. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med., 2002, 34, 451.
122. Rosenson, R.S.; Tangney, C.C.; Casey, L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 1999, 353, 983.
123. Shimada, K.; Miyauchi, K.; Daida, H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation, 2004, 109, 213.
124. Hakamada-Taguchi, R.; Uehara, Y.; Kuribayashi, K.; Numabe, A.; Saito, K.; Negoro, H.; Fujita, T.; Toyo-oka, T.; Kato, T. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res., 2003, 191, 319.
125. Chung, C.P.; Avalos, I.; Raggi, P.; Stein, C.M. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol., 2007, 26, 1228.
126. Brooks, P.M. The burden of musculoskeletal disease--a global perspective. Clin. Rheumatol., 2006, 25, 778.
127. Wick, G.; Knoflach, M.; Xu, Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu. Rev. Immunol., 2004, 22, 361.
128. Toh, M.L.; Miossec, P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr. Opin. Rheumatol., 2007, 19, 284.
129. Nagashima, T.; Okazaki, H.; Yudoh, K.; Matsuno, H.; Minota, S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum., 2006, 54, 579.
130. Tikiz, C.; Utuk, O.; Pirildar, T.; Bayturan, O.; Bayindir, P.; Taneli, F.; Tikiz, H.; Tuzun, C. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J. Rheumatol., 2005, 32, 2095.
131. Okamoto, H.; Koizumi, K.; Kamitsuji, S.; Inoue, E.; Hara, M.; Tomatsu, T.; Kamatani, N.; Yamanaka, H. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol., 2007, 34, 964.
132. Maki-Petaja, K.M.; Booth, A.D.; Hall, F.C.; Fallace, S.M.L.; Brown, J.; McEniery, C.M.; Wilkinson, I.B. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol., 2007, 50, 852.
133. Turesson, C.; Jacobsson, L.T.; Matteson, E.L. Cardiovascular comorbidity in rheumatic diseases. Vasc. Health. Risk Manag., 2008, 4, 605.
134. Abou-Raya, A.; Abou-Raya, S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun.. Rev. 2006, 5, 331.
135. Suchak, R.; Benson, K.; Swale, V. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin. Exp. Dermatol., 2007, 32, 589.
136. Sarzi-Puttini, P.; Atzeni, F.; Capsoni, F.; Lubrano, E.; Doria, A. Drug-induced lupus erythematosus. Autoimmunity, 2005, 38, 507.
137. Gullu, S.; Emral, R.; Bastemir, M.; Parkes, A.B.; Lazarus, J.H. In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis. Eur. J. Endocrinol., 2005, 153, 41.
138. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78.
139. Aktas, O.; Waiczies, S.; Smorodchenko, A.; Dorr, J.; Seeger, B.; Prozorovski, T.; Sallach, S.; Endres, M.; Brocke, S.; Nitsch, R.; Zipp, F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med., 2003, 197, 725.
140. Stanislaus, R.; Gilg, A.G.; Singh, A.K.; Singh, I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci. Lett., 2002, 333, 167.
141. Greenwood, J.; Walters, C.E.; Pryce, G.; Kanuga, N.; Beraud, E.; Baker, D.; Adamson, P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J., 2003, 17, 905.
142. Sena, A.; Pedrosa, R.; Graça Morais, M. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol., 2003, 250, 754.
143. Kim, H.J.; Ifergan, I.; Antel, J.P.; Seguin, R.; Duddy, M.; Lapierre, Y.; Jalili, F.; Bar-Or, A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol., 2004, 172, 7144.
144. Paul, F.; Waiczies, S.; Wuerfel, J.; Bellmann-Strobl, J.; Dörr, J.; Waiczies, H.; Haertle, M.; Wernecke, K.D.; Volk, H.; Aktas, O.; Zipp, F. Oral high-dose atorvastatin treatment in relapsingremitting multiple sclerosis. PloS ONE, 2008, 3, e1928.
145. Zamvil, S.; Atorvastatin (lipitor) therapy in patients with clinically isolated syndrome (CIS) at risk for multiple sclerosis (STAYCIS). Available from: http://www.immunetolerance.org/studies/atorvastatin-lipitor-therapy- patients-with-clinically-isolated-syndromecis-risk-multiple-sc
146. Zacco, A.; Togo, J.; Spence, K.; Ellis, A.; Lloyd, D.; Furlong, S.; Piser, T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci., 2003, 23, 11104.
147. Paintlia, A.S.; Paintlia, M.K.; Khan, M.; Vollmer, T.; Singh, A.K.; Singh, I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J., 2005, 19, 1407.
148. Menge, T.; Hartung, H.; Stuve, O. Statins--a cure-all for the brain? Nat. Rev. Neurosci., 2005, 6, 325.
149. Jick, H.; Zornberg, G.L.; Jick, S.S.; Seshadri, S.; Drachman, D.A. Statins and the risk of dementia. Lancet, 2000, 356, 1627.
150. Wolozin, B.; Kellman, W.; Ruosseau, P.; Celesia, G.G.; Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 2000, 57, 1439.
151. Kojro, E.; Gimpl, G.; Lammich, S.; Marz, W.; Fahrenholz, F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. USA, 2001, 98, 5815.
152. Van der Hilst, J.C.; Kluve-Beckerman, B.; Bodar, E.J.; Van der Meer, J.W.; Drenth, J.P.; Simon, A. Lovastatin inhibits formation of AA amyloid. J. Leukoc. Biol., 2008, 83, 1295.
153. Hoglund, K.; Thelen, K.M.; Syversen, S.; Sjogren, M.; von Bergmann, K.; Wallin, A.; Vanmechelen, E.; Vanderstichele, H.; Lutjohann, D.; Blennow, K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2005, 19, 256.
154. Cibicková, L.; Palicka, V.; Cibicek, N.; Cermáková, E.; Micuda, S.; Bartosová, L.; Jun, D. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol. Res., 2007, 56, 765.
155. Shepherd, J.; Blauw, G.J.; Murphy, M.B.; Bollen, E.L.E.M.; Buckley, B.M.; Cobbe, S.M.; Ford, I.; Gaw, A.; Hyland, M.; Jukema, J.W.; Kamper, A.M.; Macfarlane, P.W.; Meinders, A.E.; Norrie, J.; Packard, C.J.; Perry, I.J.; Stott, D.J.; Sweeney, B.J.; Twomey, C.; Westendorp, R.G.J.; on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002, 360, 1623
156. Collins, R.; Armitage, J.; Parish, S.; Sleigh, P.; Peto, R.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003, 361, 2005.
157. Sparks, D.L.; Sabbagh, M.N.; Connor, D.J.; Lopez, J.; Launer, L.J.; Browne, P.; Wasser, D.; Johnson-Traver, S.; Lochhead, J.; Ziolwolski, C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol., 2005 62, 753.
158. Jones, R.W.; Kivipelto, M.; Feldman, H.; Sparks, L.; Doody, R.; Waters, D.D.; Hey-Hadavi, J.; Breazna, A.; Schindler, R.J.; Ramos, H.; LEADe investigators. The atorvastatin/donepezil in alzheimer's disease study (LEADe): design and baseline characteristics. Alzheimers dement., 2008, 4, 145.
159. Remick, D.G. Pathophysiology of sepsis. Am. J. Pathol., 2007, 170, 1435.
160. Chaudhry, M.Z.; Wang, J.H.; Blankson, S.; Redmond, H.P. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg. Infect. (Larchmt), 2008, 9, 183.
161. Yasuda, H.; Yuen, P.S.; Hu, X.; Zhou, H.; Star, R.A. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int., 2006, 69, 1535.
162. Merx, M.W.M.; Liehn, E.A.M.; Graf, J.M.; van de Sandt, A.; Schaltenbrand, M.; Schrader, J.; Hanrath, P.; Weber, C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation, 2005, 112, 117.
163. Merx, M.W.M.; Liehn, E.A.M.; Janssens, U.M.; Lütticken, R.; Schrader, J.; Hanrath, P.; Weber, C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation, 2004, 109, 2560.
164. Chello, M.; Patti, G.; Candura, D.; Mastrobuoni, S.; Di Sciascio, G.; Agrò, F.; Carassiti, M.; Covino, E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit. Care Med., 2006, 34, 660.
165. Gupta, R.; Plantinga, L.C.; Fink, N.E.; Melamed, M.L.; Coresh, J.; Fox, C.S.; Levin, N.W.; Powe, N.R. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA, 2007, 297, 1455.
166. Hackam, D.G.; Mamdani, M.; Li, P.; Redelmeier, D.A. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet, 2006, 367, 413.
167. Almog, Y.M.; Shefer, A.M.; Novack, V.M.; Maimon, N.; Barski, L.; Eizinger, M.; Friger, M.; Zeller, L.; Danon, A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 2004, 110, 880.
168. van de Garde, E.M.; Hak, E.; Souverein, P.C.; Hoes, A.W.; van den Bosch, J.M.; Leufkens, H.G. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax, 2006, 61, 957.
169. Schlienger, R.G.; Fedson, D.S.; Jick, S.S.; Jick, H.; Meier, C.R. Statins and the risk of pneumonia: a population-based, nested casecontrol study. Pharmacotherapy, 2007, 27, 325.
170. Mortensen, E.M.; Restrepo, M.I.; Anzueto, A.; Pugh, J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir. Res., 2005, 6, 82.
171. Majumdar, S.R.; McAlister, F.A.; Eurich, D.T.; Padwal, R.S.; Marrie, T.J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ, 2006, 333, 999.